MiNK Therapeutics, Inc. - Common Stock (INKT)

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with Opdivo.

“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company said.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million.

Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.